Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 4
1995 3
1996 1
1999 1
2000 1
2002 2
2003 3
2004 4
2005 5
2006 4
2007 3
2008 7
2009 5
2010 9
2011 12
2012 8
2013 8
2014 11
2015 19
2016 20
2017 15
2018 18
2019 19
2020 19
2021 30
2022 30
2023 21
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

271 results

Results by year

Filters applied: . Clear all
Page 1
Pulmonary hypertension in chronic lung disease and hypoxia.
Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, Olsson KM, Peacock AJ, Pepke-Zaba J, Provencher S, Weissmann N, Seeger W. Nathan SD, et al. Eur Respir J. 2019 Jan 24;53(1):1801914. doi: 10.1183/13993003.01914-2018. Print 2019 Jan. Eur Respir J. 2019. PMID: 30545980 Free PMC article. Review.
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.
Waxman A, Restrepo-Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A, Allen R, Feldman J, Argula R, Smith P, Rollins K, Deng C, Peterson L, Bell H, Tapson V, Nathan SD. Waxman A, et al. Among authors: nathan sd. N Engl J Med. 2021 Jan 28;384(4):325-334. doi: 10.1056/NEJMoa2008470. Epub 2021 Jan 13. N Engl J Med. 2021. PMID: 33440084 Clinical Trial.
Response.
Nathan SD, Waxman AB. Nathan SD, et al. Chest. 2023 Jul;164(1):e22. doi: 10.1016/j.chest.2023.04.016. Chest. 2023. PMID: 37423705 No abstract available.
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.
Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U. Lancaster LH, et al. Among authors: nathan sd. Eur Respir Rev. 2017 Dec 6;26(146):170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31. Eur Respir Rev. 2017. PMID: 29212837 Free PMC article. Review.
Response.
Nathan SD, Shen E, Deng C. Nathan SD, et al. Chest. 2024 May;165(5):e162. doi: 10.1016/j.chest.2024.01.004. Chest. 2024. PMID: 38724161 No abstract available.
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group. King TE Jr, et al. Among authors: nathan sd. N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18. N Engl J Med. 2014. PMID: 24836312 Free article. Clinical Trial.
Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study.
Waxman A, Restrepo-Jaramillo R, Thenappan T, Engel P, Bajwa A, Ravichandran A, Feldman J, Hajari Case A, Argula RG, Tapson V, Smith P, Deng C, Shen E, Nathan SD. Waxman A, et al. Among authors: nathan sd. Eur Respir J. 2023 Jun 29;61(6):2202414. doi: 10.1183/13993003.02414-2022. Print 2023 Jun. Eur Respir J. 2023. PMID: 37080567 Free PMC article. Clinical Trial.
Response.
Nathan SD, Brown AW, Weir NA. Nathan SD, et al. Chest. 2014 Jun;145(6):1440-1441. doi: 10.1378/chest.14-0720. Chest. 2014. PMID: 24889459 Free PMC article. No abstract available.
271 results